Skip to main content
Top
Published in: Supportive Care in Cancer 6/2012

01-06-2012 | Short Communication

Gastrointestinal stromal tumor: psychosocial characteristics and considerations

Authors: Lori Wiener, Haven Battles, Sima Zadeh, Carly J. Smith, Lee J. Helman, Su Young Kim

Published in: Supportive Care in Cancer | Issue 6/2012

Login to get access

Abstract

Objective

Gastrointestinal stromal tumors (GIST) are very rare, especially within the pediatric population. The National Institutes of Health initiated a multidisciplinary clinic to bring together a worldwide group of healthcare providers with experience in the study and treatment of GIST in order to better understand the disease and to examine whether this is a population at psychosocial risk.

Methods

Seven GIST clinics have been held to date. Participants completed a GIST Psychosocial Assessment containing items covering demographic factors, family stressors, general health, psychosocial concerns, psychiatric history, and self-identified needs. Our sample consists of 60 adult patients (ages 18–66) and 18 pediatric patients (ages 9–17).

Results

Living with pain at least a few days a week was endorsed by those whose self-reported health status was good to excellent (49% of the adult cohort and 25% of the pediatric cohort). Pain was significantly associated with anxiety, difficulties with family relationships, behavior problems, and psychotropic medication use. Body image and appearance concerns were endorsed by over half of the cohort. Post-trauma symptoms were prevalent for those newly diagnosed and those living with GIST for over 15 years.

Conclusions

This is the first study to explore the psychosocial impact of GIST. Individuals living with GIST experience chronic pain, post-trauma symptoms and significant anxiety along with an expressed need for interventions to help them manage their anxiety. Due to the chronic nature of this disease, the GIST population is at risk for long-term psychological distress. Psychosocial interventions in pediatric and adult care settings are offered.
Literature
1.
go back to reference Demitri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, JoensuuH JI, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, con Mehren M, Wayne JD, Zalcbery J, NCCN Task Force (2007) NCCN Take Force Report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(2):S1–S29 Demitri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, JoensuuH JI, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, con Mehren M, Wayne JD, Zalcbery J, NCCN Task Force (2007) NCCN Take Force Report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(2):S1–S29
2.
go back to reference Pappo AS, Janeway KA (2009) Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am 23:15–34PubMedCrossRef Pappo AS, Janeway KA (2009) Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am 23:15–34PubMedCrossRef
3.
go back to reference Kaemmer DA, Otto J, Lassay L, Steinau G, Klink C, Junge K, Klinge U, Schumpelick V (2009) The gist of literature on pediatric GIST: review of clinical presentation. J Pediatr Hematol Oncol 31(2):108–112PubMedCrossRef Kaemmer DA, Otto J, Lassay L, Steinau G, Klink C, Junge K, Klinge U, Schumpelick V (2009) The gist of literature on pediatric GIST: review of clinical presentation. J Pediatr Hematol Oncol 31(2):108–112PubMedCrossRef
4.
go back to reference Spiegel B, Schoenfeld P, Nabiloff B (2007) Systematic review: the prevalence of suicidal behavior in patients with chronic abdominal and irritable bowel syndrome. Aliment Pharmacol Ther 26:183–193PubMedCrossRef Spiegel B, Schoenfeld P, Nabiloff B (2007) Systematic review: the prevalence of suicidal behavior in patients with chronic abdominal and irritable bowel syndrome. Aliment Pharmacol Ther 26:183–193PubMedCrossRef
5.
go back to reference Youssef NN, Murphy TG, Langseder AL, Strauss RS (2006) Quality of life for children with functional abdominal pain: a comparison study of patients’ and parents’ perceptions. Pediatrics 117:54–59PubMedCrossRef Youssef NN, Murphy TG, Langseder AL, Strauss RS (2006) Quality of life for children with functional abdominal pain: a comparison study of patients’ and parents’ perceptions. Pediatrics 117:54–59PubMedCrossRef
6.
go back to reference Roth-Isigkeit A, Thyen U, Stöven H, Schwarzenberger J, Schmucker P (2005) Pain among children and adolescents: restrictions in daily living and triggering factors. Pediatrics 115(4):1118–1118 Roth-Isigkeit A, Thyen U, Stöven H, Schwarzenberger J, Schmucker P (2005) Pain among children and adolescents: restrictions in daily living and triggering factors. Pediatrics 115(4):1118–1118
7.
go back to reference Campo JV, Comer DM, Jansen-McWilliams L, Gardner W, Kelleher KJ (2002) Recurrent pain, emotional distress, and health service use in childhood. Pediatrics 141:76–83CrossRef Campo JV, Comer DM, Jansen-McWilliams L, Gardner W, Kelleher KJ (2002) Recurrent pain, emotional distress, and health service use in childhood. Pediatrics 141:76–83CrossRef
8.
go back to reference Hirota S, Isozaki K, Moriyama Y, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain of function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577–580PubMedCrossRef Hirota S, Isozaki K, Moriyama Y, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain of function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577–580PubMedCrossRef
9.
go back to reference Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607):708–710PubMedCrossRef Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607):708–710PubMedCrossRef
10.
go back to reference Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097–1104PubMedCrossRef Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097–1104PubMedCrossRef
11.
go back to reference Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VHC, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CDM, Crowley JJ, Borden EC (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4):626–632PubMedCrossRef Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VHC, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CDM, Crowley JJ, Borden EC (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4):626–632PubMedCrossRef
12.
go back to reference Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrish MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338PubMedCrossRef Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrish MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338PubMedCrossRef
13.
go back to reference Janeway KA, Matthews DC, Butrynski JE, D’Amato GZ, Agresta S, Garrett C, Corless CL, Albritton KH, Demetri GD (2006) Sunitinib treatment of pediatric metastatic GIST after failure of imatinib. J Clin Oncol 24:524S–524S Janeway KA, Matthews DC, Butrynski JE, D’Amato GZ, Agresta S, Garrett C, Corless CL, Albritton KH, Demetri GD (2006) Sunitinib treatment of pediatric metastatic GIST after failure of imatinib. J Clin Oncol 24:524S–524S
14.
go back to reference Pai AL, Patiño-Fernández AM, McSherry M, Beele D, Alderfer MA, Reilly AT, Hwang WT, Kazak AE (2008) The Psychosocial Assessment Tool (PAT2.0): psychometric properties of a screener for psychosocial distress in families of children newly diagnosed with cancer. J Pediatr Psychol 33:50–62PubMedCrossRef Pai AL, Patiño-Fernández AM, McSherry M, Beele D, Alderfer MA, Reilly AT, Hwang WT, Kazak AE (2008) The Psychosocial Assessment Tool (PAT2.0): psychometric properties of a screener for psychosocial distress in families of children newly diagnosed with cancer. J Pediatr Psychol 33:50–62PubMedCrossRef
16.
go back to reference IOM (Institute of Medicine) (2011) Relieving pain in America: a blueprint for transforming prevention, care, education and research. Committee on Advancing Pain Research, Care, and Education Board on Health Sciences Policy, The National Academies Press, Washington, DC IOM (Institute of Medicine) (2011) Relieving pain in America: a blueprint for transforming prevention, care, education and research. Committee on Advancing Pain Research, Care, and Education Board on Health Sciences Policy, The National Academies Press, Washington, DC
17.
go back to reference Nissen MJ, Swenson KK, Ritz LJ, Farrell JB, Sladek ML, Lally RM (2001) Quality of life after breast cancer carcinoma surgery: a comparison of three surgical procedures. Cancer 91(7):1238–1246PubMedCrossRef Nissen MJ, Swenson KK, Ritz LJ, Farrell JB, Sladek ML, Lally RM (2001) Quality of life after breast cancer carcinoma surgery: a comparison of three surgical procedures. Cancer 91(7):1238–1246PubMedCrossRef
18.
go back to reference Kazak AE, Barakat LP, Hwang W, Ditaranto S, Biros D, Beele D, Kersun L, Hocking MC, Reilly A (2011) Association of psychosocial risk screening in pediatric cancer with psychosocial services provided. Psycho-Oncol 20:715–723. doi:10.1002/pon.1972 CrossRef Kazak AE, Barakat LP, Hwang W, Ditaranto S, Biros D, Beele D, Kersun L, Hocking MC, Reilly A (2011) Association of psychosocial risk screening in pediatric cancer with psychosocial services provided. Psycho-Oncol 20:715–723. doi:10.​1002/​pon.​1972 CrossRef
Metadata
Title
Gastrointestinal stromal tumor: psychosocial characteristics and considerations
Authors
Lori Wiener
Haven Battles
Sima Zadeh
Carly J. Smith
Lee J. Helman
Su Young Kim
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 6/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1426-7

Other articles of this Issue 6/2012

Supportive Care in Cancer 6/2012 Go to the issue

Letter to the Editor

Letter to the Editor

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine